Commentary|Articles|November 17, 2026

Perioperative Targeted Therapy Fills the Immunotherapy Gap in Oncogene-Driven Early-Stage NSCLC

Fact checked by: Caroline Seymour
Listen
0:00 / 0:00

Elaine Shum, MD, discusses biomarker testing, neoadjuvant vs adjuvant osimertinib, and recurrence and ctDNA in oncogene-driven early-stage NSCLC.

For patients with resectable non–small cell lung cancer (NSCLC) harboring EGFR, ALK, or RET alterations, getting the most out of curative-intent treatment depends on identifying the driver in every tumor and matching patients with the right TKI before or after surgery, according to Elaine Shum, MD.

"We're supposed to be testing for these mutations before pursuing any of those treatments so that [these patients] don't get immunotherapy," Shum said in an exclusive interview with OncLive® at the 21st Annual New York Lung Cancers Symposium. "But it leaves the big question of, if we can't use immunotherapy, then what's in our toolbox?"

With respect to EGFR, in the phase 3 NeoADAURA trial (NCT04351555), neoadjuvant osimertinib (Tagrisso) plus chemotherapy (n = 121) and osimertinib monotherapy (n = 117) produced major pathological response (MPR) rates of 26% (95% CI, 18%-34%) and 25% (95% CI, 17%-34%), respectively, vs 2% (95% CI, 0%-6%) with placebo plus chemotherapy (n = 120) in patients with resectable, EGFR-mutated, stage II to IIIB NSCLC.1 Grade 3 or higher adverse effects of any cause occurred during the neoadjuvant period in 36%, 13%, and 33% of patients in the respective arms.

In the adjuvant setting, an exploratory 8-year landmark analysis of the phase 3 ADAURA trial (NCT02511106) presented at the 2026 IASLC World Conference on Lung Cancer showed 8-year overall survival rates of 74% (95% CI, 67%-80%) with 3 years of adjuvant osimertinib (n = 233) vs 58% (95% CI, 50%-65%) with placebo (n = 237) in patients with stage II to IIIA disease (HR, 0.53; 95% CI, 0.38-0.75).2 To better elucidate the optimal duration of adjuvant therapy, the ongoing phase 2 TARGET trial (NCT05526755) is evaluating 5 years of adjuvant osimertinib in patients with resected, EGFR-mutated, stage II to IIIB NSCLC.3

In the interview, Shum discussed biomarker testing in early-stage disease, choosing between neoadjuvant and adjuvant osimertinib, adjuvant treatment duration and recurrence, and the role of circulating tumor DNA (ctDNA).

Shum is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, director of Cancer Screening Programs, and a thoracic medical oncologist at NYU Langone Health's Perlmutter Cancer Center in New York, New York.

OncLive: What does getting the most out of treatment mean for patients with oncogene-driven early-stage NSCLC?

Shum: In early-stage NSCLC, we've seen a lot of advancements with perioperative approaches, particularly with chemotherapy and immunotherapy. For oncogenic drivers such as EGFR, ALK, and RET, there are more options in the adjuvant setting. We tend not to use immunotherapy for these patients in the metastatic setting, so there's much more hesitation to use it in the early-stage setting. The question is how we can continue to push the needle in the neoadjuvant and adjuvant settings, like we have with immunotherapy.

Adjuvant targeted therapy for EGFR-, ALK-, and RET-altered disease has been practice changing. Use of adjuvant chemotherapy varied for each alteration, but adjuvant targeted therapy improved disease-free survival, and in EGFR-mutant disease, overall survival as well. We hope to see targeted therapies in that setting for other rare alterations, like HER2 exon 20 insertions, because we usually don't have immunotherapy in our toolbox for those patients.

In the neoadjuvant setting, NeoADAURA evaluated osimertinib as monotherapy and in combination with chemotherapy, which shows that there are differences in the biology of oncogene-driven lung cancers. There's a lot of excitement about exploring targeted therapy in the early-stage setting, and it also informs what we're doing in the metastatic setting as we learn more about the effects of these drugs on surgical specimens.

Perioperative Targeted Therapy in Oncogene-Driven Early-Stage NSCLC: Key Highlights

  • Shum tests every early-stage tumor, including stage I, and relies on tissue because a negative liquid biopsy does not rule out a driver alteration.
  • Neoadjuvant osimertinib with or without chemotherapy raised MPR rates to 26% and 25% vs 2% with chemotherapy alone in NeoADAURA, making it worth considering for stage III, N2 disease.
  • Until TARGET reports, decisions about continuing adjuvant osimertinib beyond 3 years hinge on tolerability, the risk of brain recurrence after stopping, and financial toxicity.

How do you ensure biomarker testing is done on early-stage tumors, including stage IB tumors?

With all the neoadjuvant and adjuvant treatments available, biomarker testing should be done before you start anything, so you have a better understanding of what you're dealing with. Thankfully, we are seeing more uptake of biomarker testing in the early-stage setting.

It can be challenging to test pre-surgical biopsies if the samples are too small, but try to send those off, especially if you're considering neoadjuvant therapy. Testing is much easier on surgical specimens, which should have more tumor tissue, so if you can't test the pre-surgical biopsy, send off the surgical specimen afterward. I routinely test all my patients with early-stage disease, including stage I disease. I tell patients that it helps us understand the biology and be prepared if recurrence happens.

Liquid biopsy is widely used in the metastatic setting, but results vary in the early-stage setting. Particularly for stage I disease, it is much harder to detect alterations, given the nature of such early-stage disease. I caution that a negative liquid biopsy does not mean the patient doesn't have a driver mutation within their tumor. Tissue testing is recommended.

How do you decide between neoadjuvant osimertinib, adjuvant osimertinib, or both for patients with resectable EGFR-mutant disease?

ADAURA and now NeoADAURA give us data for adjuvant and neoadjuvant osimertinib. In my practice, when patients present with more advanced disease—stage III, and particularly N2 disease—I more seriously consider a neoadjuvant approach as opposed to upfront resection. For a patient with EGFR-mutant, N2 disease, I would already be considering neoadjuvant therapy.

The next question is which neoadjuvant therapy. Neoadjuvant osimertinib with or without chemotherapy is not yet FDA approved, so for someone considering neoadjuvant therapy, the option is neoadjuvant chemotherapy alone. However, NeoADAURA showed that adding osimertinib improves MPR, and there were some pathological complete responses [pCRs] in the osimertinib-containing arms. That makes it enticing to consider osimertinib in the neoadjuvant setting.

Then the question is whether to combine osimertinib with chemotherapy. The data showed comparable MPR results, and even slightly more pCRs with osimertinib alone. The decision takes patient factors such as performance status into account, and the toxicity of combining osimertinib with chemotherapy is going to be greater than that of osimertinib monotherapy. However, a patient with stage II or III disease who didn't receive neoadjuvant therapy would be recommended adjuvant chemotherapy, so giving chemotherapy upfront with osimertinib is something to consider. You can also get more information from the surgical specimen after neoadjuvant osimertinib and chemotherapy to inform future treatment.

Adjuvant osimertinib is given for 3 years. Would you treat longer or stop sooner in some patients with EGFR-mutant disease?

ADAURA established 3 years of adjuvant osimertinib, and many of my patients have reached that 3-year mark. I review what ADAURA showed with each of them, and I mention the ongoing TARGET study, which is looking at extending treatment from 3 years to 5 years. Without those data, the conversation depends on what patients are experiencing on therapy. If they've made it to 3 years, they've generally tolerated the drug without major concerns.

In ADAURA, recurrences in the brain occurred after patients completed osimertinib, so I talk about that as a possibility. We also discuss ongoing potential adverse effects and financial toxicity; targeted therapy is not inexpensive. Many patients want to continue beyond 3 years because of their anxiety about recurrence after stopping osimertinib. We'll wait to see what TARGET shows.

How do you handle recurrence after adjuvant TKI therapy, and does the timing of recurrence matter?

That is a newer challenge. If patients experience recurrence on adjuvant targeted therapy, the approach depends on whether they received adjuvant chemotherapy first. If they had not, adding chemotherapy to their targeted therapy or giving chemotherapy alone is something to consider. Reprofiling the recurrence is also important to identify any resistance mutations that have arisen on targeted therapy and help inform what comes next.

If someone has received adjuvant chemotherapy, the timing of that chemotherapy relative to the recurrence matters. If the recurrence occurs several years later, it might not be unreasonable to consider rechallenging with a similar backbone. However, this is where antibody-drug conjugates may emerge to address an unmet need for patients who have already received chemotherapy. For example, consider a patient with EGFR-mutant disease who received adjuvant chemotherapy and adjuvant osimertinib and then had a recurrence. Is that where something like datopotamab deruxtecan-dlnk [Datroway] might fit in? We're all gaining more experience as more patients receive adjuvant osimertinib.

What role should ctDNA play in deciding how long to give adjuvant therapy?

We're excited by the utility and convenience of ctDNA. In the early-stage setting, however, it's tricky—especially for stage I tumors—to rely on some of the platforms to tell us whether recurrence is present before imaging might. We need more minimal residual disease testing with much more resolution. Many studies are looking at ctDNA before and after surgery. Patients with ctDNA detected after surgery may have higher-risk disease, for which adjuvant chemotherapy or targeted therapy will be more strongly considered.

Tumor-informed assays are also important to potentially detect recurrence earlier than imaging, and I have been using them more in my clinic. However, there's still a lot of debate about the best type of testing in this setting. We would love to see these assays used to determine the duration of adjuvant treatment. For adjuvant immunotherapy, is 1 year necessary, or is 6 months enough? With targeted therapy, is 3 years enough? Assays we can reliably depend on to show us the evolution of the tumor would be very helpful.

References

  1. He J, Tsuboi M, Weder W, et al; NeoADAURA Investigators. Neoadjuvant osimertinib for resectable EGFR-mutated non–small cell lung cancer. J Clin Oncol. 2025;43(26):2875-2887. doi:10.1200/JCO-25-00883
  2. Wu YL, Majem M, John T, et al. Adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC: exploratory 8-year overall survival landmark update from the ADAURA trial. J Thorac Oncol. Published online September 13, 2026. doi:10.1016/j.jtho.2026.104179
  3. A study of 5 years of adjuvant osimertinib in completely resected epidermal growth factor receptor mutation (EGFRm) non-small cell lung carcinoma (NSCLC) (TARGET). ClinicalTrials.gov. Updated August 3, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT05526755

Related to this article